BioNexus Gene Lab Corp. (NASDAQ:BGLC) Short Interest Update

by · The Cerbat Gem

BioNexus Gene Lab Corp. (NASDAQ:BGLC – Get Free Report) was the recipient of a significant increase in short interest in September. As of September 15th, there was short interest totaling 13,030 shares, an increase of 74.0% from the August 31st total of 7,488 shares. Based on an average daily volume of 3,712 shares, the short-interest ratio is presently 3.5 days. Approximately 0.4% of the company’s stock are sold short.

Analyst Ratings Changes

Separately, Weiss Ratings cut shares of BioNexus Gene Lab from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, September 18th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Sell”.

View Our Latest Research Report on BGLC

BioNexus Gene Lab Trading Down 1.6%

NASDAQ BGLC opened at $1.20 on Friday. The company has a market cap of $3.52 million, a price-to-earnings ratio of -0.95 and a beta of 4.22. BioNexus Gene Lab has a 52 week low of $1.07 and a 52 week high of $5.89. The business has a 50 day moving average price of $1.47 and a 200-day moving average price of $1.91. The company has a quick ratio of 5.28, a current ratio of 6.08 and a debt-to-equity ratio of 0.01.

BioNexus Gene Lab (NASDAQ:BGLC – Get Free Report) last issued its earnings results on Friday, August 14th. The company reported ($0.12) earnings per share for the quarter. BioNexus Gene Lab had a negative return on equity of 32.92% and a negative net margin of 82.38%.The firm had revenue of $0.08 million for the quarter.

About BioNexus Gene Lab

(Get Free Report)

BioNexus Gene Lab Corp. (NASDAQ:BGLC) is a biotechnology and molecular diagnostics company focused on developing genetic tests intended to support the early detection of cancer and other diseases. Its diagnostic work uses blood-based and molecular analysis to identify biological indicators that may help healthcare providers assess disease risk and guide further evaluation.

The company operates through two primary business areas: Molecular Diagnostics and Chemical Trading. The Molecular Diagnostics segment develops and commercializes genetic testing products, while the Chemical Trading segment distributes industrial chemicals and related products to customers in its served markets.

BioNexus Gene Lab is headquartered in Kuala Lumpur, Malaysia, and its operations have included activities in the Malaysian market.

See Also